Karolinska Development's portfolio company Dilafor progresses with FDA and EMA for new labor drug.

From GlobeNewswire: 2025-01-30 02:50:00

Karolinska Development AB’s portfolio company Dilafor has completed regulatory meetings with the FDA and European Health Agencies for its drug candidate tafoxiparin, aimed at labor priming. The FDA and EMA have aligned on the Phase 3 study design, focusing on the drug’s unique mechanism of action. The drug offers a new treatment option for labor priming, potentially reducing complications and costs associated with labor induction. Karolinska Development aims to support breakthrough medical innovations in the Nordic region, with a focus on improving patient outcomes while providing returns for shareholders.



Read more at GlobeNewswire: Karolinska Development’s portfolio company Dilafor advances